KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue: 2009-2024

Historic Non-Current Deffered Revenue for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $185.7 million.

  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue rose 5.69% to $219.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.2 million, marking a year-over-year increase of 5.69%. This contributed to the annual value of $185.7 million for FY2024, which is 46.57% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $185.7 million for FY2024, which was up 46.57% from $126.7 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue's 5-year high stood at $185.7 million during FY2024, with a 5-year trough of $57.8 million in FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Non-Current Deffered Revenue averaged around $127.4 million, with its median value being $126.7 million (2023).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Non-Current Deffered Revenue crashed by 88.66% in 2020 and then soared by 81.52% in 2023.
  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $57.8 million in 2020, then rose by 26.82% to $73.3 million in 2021, then dropped by 4.77% to $69.8 million in 2022, then soared by 81.52% to $126.7 million in 2023, then spiked by 46.57% to $185.7 million in 2024.